Just reading the previous two announcements, Malcolm McColl states that VLA are wanting to proceed to a pivotal phase three trial in melanoma patients, the investor presentation notes progressing MITCI into a pivotal study. Does mean the intention is to take Yervoy+Cavatak to phase 3 or am I missreading the comments?
